The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights
Open accessAbstract
IMPORTANCE: Approximately half of newly-diagnosed hepatocellular carcinoma (HCC) cases in the world occur in China, with hepatitis B virus (HBV) infection being the predominant risk factor. Recently, the guidelines for the management of Chinese HCC patients were updated. OBJECTIVE: The past decade has witnessed a great improvement in the management of hepatocellular carcinoma (HCC). This study reviews the recommendations in the 2019 Chinese guidelines and makes comparison with the practices from the Western world. EVIDENCE REVIEW: The updated recommendations on the surveillance, diagnosis, and treatment algorithm of HCC in the 2019 Chinese guidelines were summarized, and comparisons among the updated Chinese guidelines, the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD) guidelines were made. FINDINGS: Besides imaging and pathological diagnoses, novel biomarkers like the seven-micro-RNA panel are advocated for early diagnoses and therapeutic efficacy evaluation in the updated Chinese guidelines. The China liver cancer (CNLC) staging system, proposed in the 2017 guidelines, continues to be the standard model for patient classification, with subsequent modifications and updates being made in treatment allocations. Compared to the Barcelona Clinic Liver Cancer (BCLC) system, the CNLC staging system employs resection, transplantation, and transarterial chemoembolization (TACE) for more progressed HCC. TACE in combination with other regional therapies like ablation or with systemic therapies like sorafenib are also encouraged in select patients in China. The systemic treatments for HCC have evolved considerably since lenvatinib, regorafenib, carbozantinib, ramucirumab and immune checkpoint inhibitors (ICIs)were first prescribed as first-line or second-line agents. CONCLUSIONS AND RELEVANCES: Novel biomarkers, imaging and operative techniques are recommended in the updated Chinese guideline. More aggressive treatment modalities are suggested for more progressed HBV-related HCC in China.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497
Marrero, J. A., Kulik, L. M., Sirlin, C. B., Zhu, A. X., Finn, R. S., Abecassis, M. M., Roberts, L. R., & Heimbach, J. K. (2018) · Hepatology · doi:10.1002/hep.29913 · Cited by 4,539
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Zhou, M., Wang, H., Zeng, X., Yin, P., Zhu, J., Chen, W., Li, X., Wang, L., Wang, L., Liu, Y., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30427-1 · Cited by 3,639
Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30351-6 · Cited by 2,479 · cited 1×
“Based on the promising results from phase II of the CHECKMATE-040 and KEYNOTE-224 trials, the AASLD has recommended PD-1 inhibitors, nivolumab and pembrolizumab, as second-line therapies for sorafenibexperienced patients (88,89).”
ResultCabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
Abou-Alfa, G. K., Meyer, T., Cheng, A.-L., El-Khoueiry, A. B., Rimassa, L., Ryoo, B.-Y., Cicin, I., Merle, P., Chen, Y., Park, J.-W., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1717002 · Cited by 2,344
Yao, F. Y., Ferrell, L., Bass, N. M., Watson, J. J., Bacchetti, P., Venook, A., Ascher, N. L., & Roberts, J. P. (2001) · Hepatology · doi:10.1053/jhep.2001.24563 · Cited by 2,262
Omata, M., Cheng, A.-L., Kokudo, N., Kudo, M., Lee, J. M., Jia, J., Tateishi, R., Han, K.-H., Chawla, Y. K., Shiina, S., et al. (2017) · Hepatology International · doi:10.1007/s12072-017-9799-9 · Cited by 2,171
Molecular therapies and precision medicine for hepatocellular carcinoma
Llovet, J. M., Montal, R., Sia, D., & Finn, R. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0073-4 · Cited by 1,938
Finn, R. S., Ryoo, B.-Y., Merle, P., Kudo, M., Bouattour, M., Lim, H. Y., Breder, V., Edeline, J., Chao, Y., Ogasawara, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01307 · Cited by 1,789
Zhu, A. X., Kang, Y.-K., Yen, C.-J., Finn, R. S., Galle, P. R., Llovet, J. M., Assenat, E., Brandi, G., Pracht, M., Lim, H. Y., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30937-9 · Cited by 1,662
Randomized controlled trial of screening for hepatocellular carcinoma
Zhang, B.-H., Yang, B.-H., & Tang, Z.-Y. (2004) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-004-0552-0 · Cited by 1,496
Bruix, J., Takayama, T., Mazzaferro, V., Chau, G.-Y., Yang, J., Kudo, M., Cai, J., Poon, R. T., Han, K.-H., Tak, W. Y., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00198-9 · Cited by 1,120 · cited 1×
“While adjuvant therapy following radical resection or ablation is not recommended by the AASLD or the EASL, TACE, interferon-α, or Huai’er granule are indicated as adjuvant options in China (54-58).”
MethodIntegrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma
Gao, Q., Zhu, H., Dong, L., Shi, W., Chen, R., Song, Z., Huang, C., Li, J., Dong, X., Zhou, Y., et al. (2019) · Cell · doi:10.1016/j.cell.2019.08.052 · Cited by 1,096
Self-citationClavien, P.-A., Lesurtel, M., Bossuyt, P. M., Gores, G. J., Langer, B., & Perrier, A. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70175-9 · Cited by 1,026
Ott, P. A., Bang, Y.-J., Piha-Paul, S. A., Razak, A. R. A., Bennouna, J., Soria, J.-C., Rugo, H. S., Cohen, R. B., O’Neil, B. H., Mehnert, J. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.2276 · Cited by 969 · cited 1×
“Based on the KEYNOTE-028 trial, T-cell-inflamed geneexpression, PD-L1 expression, and tumor mutational burden (TMB) can predict response to PD-1 blockade in multiple tumor types (26).”
BackgroundVilgrain, V., Pereira, H., Assenat, E., Guiu, B., Ilonca, A. D., Pageaux, G.-P., Sibert, A., Bouattour, M., Lebtahi, R., Allaham, W., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30683-6 · Cited by 834
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
Duffy, A. G., Ulahannan, S. V., Makorova-Rusher, O., Rahma, O., Wedemeyer, H., Pratt, D., Davis, J. L., Hughes, M. S., Heller, T., ElGindi, M., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.10.029 · Cited by 819
Kudo, M., Ueshima, K., Ikeda, M., Torimura, T., Tanabe, N., Aikata, H., Izumi, N., Yamasaki, T., Nojiri, S., Hino, K., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-318934 · Cited by 721
Xu, X., Zhang, H.-L., Liu, Q.-P., Sun, S.-W., Zhang, J., Zhu, F.-P., Yang, G., Yan, X., Zhang, Y.-D., & Liu, X.-S. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.02.023 · Cited by 706
Lencioni, R., Llovet, J. M., Han, G., Tak, W. Y., Yang, J., Guglielmi, A., Paik, S. W., Reig, M., Kim, D. Y., Chau, G.-Y., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.01.012 · Cited by 694
Chow, P. K. H., Gandhi, M., Tan, S.-B., Khin, M. W., Khasbazar, A., Ong, J., Choo, S. P., Cheow, P. C., Chotipanich, C., Lim, K., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.0892 · Cited by 658
Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition)
Zhou, J., Sun, H.-C., Wang, Z., Cong, W.-M., Wang, J.-H., Zeng, M.-S., Yang, J.-M., Bie, P., Liu, L.-X., Wen, T.-F., et al. (2018) · Liver Cancer · doi:10.1159/000488035 · Cited by 649
Self-citationMarrero, J. A., Kulik, L. M., Sirlin, C. B., Zhu, A. X., Finn, R. S., Abecassis, M. M., Roberts, L. R., Heimbach, J. K., et al. (2019) · Clinical Liver Disease · doi:10.1002/cld.802 · Cited by 645
Plasma MicroRNA Panel to Diagnose Hepatitis B Virus–Related Hepatocellular Carcinoma
Zhou, J., Yu, L., Gao, X., Hu, J., Wang, J., Dai, Z., Wang, J.-F., Zhang, Z., Lu, S., Huang, X., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.2697 · Cited by 635
Self-citationKudo, M., Matsui, O., Izumi, N., Iijima, H., Kadoya, M., Imai, Y., Okusaka, T., Miyayama, S., Tsuchiya, K., Ueshima, K., et al. (2014) · Liver Cancer · doi:10.1159/000343875 · Cited by 615
Qin, S., Ren, Z., Meng, Z., Chen, Z., Chai, X., Xiong, J., Bai, Y., Yang, L., Zhu, H., Fang, W., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30011-5 · Cited by 602
Self-citationLei, Z., Li, J., Wu, D., Xia, Y., Wang, Q., Si, A., Wang, K., Wan, X., Lau, W. Y., Wu, M., et al. (2016) · JAMA Surgery · doi:10.1001/jamasurg.2015.4257 · Cited by 599
Yuen, M.-F., Tanaka, Y., Fong, D. Y.-T., Fung, J., Wong, D. K.-H., Yuen, J. C.-H., But, D. Y.-K., Chan, A. O.-O., Wong, B. C.-Y., Mizokami, M., et al. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.07.023 · Cited by 584
Kudo, M., Imanaka, K., Chida, N., Nakachi, K., Tak, W.-Y., Takayama, T., Yoon, J.-H., Hori, T., Kumada, H., Hayashi, N., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.05.007 · Cited by 570
Wahl, D. R., Stenmark, M. H., Tao, Y., Pollom, E. L., Caoili, E. M., Lawrence, T. S., Schipper, M. J., & Feng, M. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.4925 · Cited by 567
Papatheodoridis, G., Dalekos, G., Sypsa, V., Yurdaydin, C., Buti, M., Goulis, J., Calleja, J. L., Chi, H., Manolakopoulos, S., Mangia, G., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.035 · Cited by 557
Qin, S., Bai, Y., Lim, H. Y., Thongprasert, S., Chao, Y., Fan, J., Yang, T.-S., Bhudhisawasdi, V., Kang, W. K., Zhou, Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.5643 · Cited by 500
Self-citationMeyer, T., Fox, R., Ma, Y. T., Ross, P. J., James, M. W., Sturgess, R., Stubbs, C., Stocken, D. D., Wall, L., Watkinson, A., et al. (2017) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(17)30156-5 · Cited by 499
Yoon, S. M., Ryoo, B.-Y., Lee, S. J., Kim, J. H., Shin, J. H., An, J. H., Lee, H. C., & Lim, Y.-S. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5847 · Cited by 446
Prospective validation of the Barcelona Clinic Liver Cancer staging system
Cillo, U., Vitale, A., Grigoletto, F., Farinati, F., Brolese, A., Zanus, G., Neri, D., Boccagni, P., Srsen, N., D'Amico, F., et al. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2005.12.015 · Cited by 425
Sun, Y.-F., Xu, Y., Yang, X.-R., Guo, W., Zhang, X., Qiu, S.-J., Shi, R.-Y., Hu, B., Zhou, J., & Fan, J. (2013) · Hepatology · doi:10.1002/hep.26151 · Cited by 404
Self-citationPrevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China
Cui, F., Shen, L., Li, L., Wang, H., Wang, F., Bi, S., Liu, J., Zhang, G., Wang, F., Zheng, H., et al. (2017) · Emerging Infectious Diseases · doi:10.3201/eid2305.161477 · Cited by 362
Finn, R. S., Merle, P., Granito, A., Huang, Y.-H., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Gerolami, R., Caparello, C., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.04.010 · Cited by 347
Tang, A., Bashir, M. R., Corwin, M. T., Cruite, I., Dietrich, C. F., Do, R. K. G., Ehman, E. C., Fowler, K. J., Hussain, H. K., Jha, R. C., et al. (2018) · Radiology · doi:10.1148/radiol.2017170554 · Cited by 319
Wang, Z., Ren, Z., Chen, Y., Hu, J., Yang, G., Yu, L., Yang, X., Huang, A., Zhang, X., Zhou, S., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2899 · Cited by 318
Self-citationWei, X., Jiang, Y., Zhang, X., Feng, S., Zhou, B., Ye, X., Xing, H., Xu, Y., Shi, J., Guo, W., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02184 · Cited by 285
Nomograms for Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection
Yang, H.-I., Sherman, M., Su, J., Chen, P.-J., Liaw, Y.-F., Iloeje, U. H., & Chen, C.-J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4456 · Cited by 281
Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma
Gao, Q., Zhu, H., Dong, L., Shi, W., Chen, R., Song, Z., Huang, C., Li, J., Dong, X., Zhou, Y., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.038 · Cited by 279
Self-citationHan, H.-S., Shehta, A., Ahn, S., Yoon, Y.-S., Cho, J. Y., & Choi, Y. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.04.005 · Cited by 270
Wang, Q., Xia, D., Bai, W., Wang, E., Sun, J., Huang, M., Mu, W., Yin, G., Li, H., Zhao, H., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.01.013 · Cited by 261
Terzi, E., Iavarone, M., Pompili, M., Veronese, L., Cabibbo, G., Fraquelli, M., Riccardi, L., De Bonis, L., Sangiovanni, A., Leoni, S., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.007 · Cited by 259
Chen, Q., Shu, C., Laurence, A. D., Chen, Y., Peng, B.-G., Zhen, Z.-J., Cai, J.-Q., Ding, Y.-T., Li, L.-Q., Zhang, Y.-B., et al. (2018) · Gut · doi:10.1136/gutjnl-2018-315983 · Cited by 246
Huo, Y. R., & Eslick, G. D. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2189 · Cited by 238
Huang, G., Lau, W. Y., Wang, Z.-G., Pan, Z.-Y., Yuan, S.-X., Shen, F., Zhou, W.-P., & Wu, M.-C. (2015) · Annals of Surgery · doi:10.1097/sla.0000000000000858 · Cited by 227
Hyun, M. H., Lee, Y., Kim, J. H., Lee, C. U., Jung, Y. K., Seo, Y. S., Yim, H. J., Yeon, J. E., & Byun, K. S. (2018) · Hepatology · doi:10.1002/hep.29883 · Cited by 219
Sharma, S. A., Kowgier, M., Hansen, B. E., Brouwer, W. P., Maan, R., Wong, D., Shah, H., Khalili, K., Yim, C., Heathcote, E. J., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.07.033 · Cited by 214
Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy
Dhanasekaran, R., Nault, J.-C., Roberts, L. R., & Zucman-Rossi, J. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.11.001 · Cited by 208
Kim, N., Cheng, J., Jung, I., Liang, J. D., Shih, Y. L., Huang, W.-Y., Kimura, T., Lee, V. H. F., Zeng, Z. C., Zhenggan, R., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.005 · Cited by 200
Wei, W., Jian, P., Li, S., Guo, Z., Zhang, Y., Ling, Y., Lin, X., Xu, L., Shi, M., Zheng, L., et al. (2018) · Cancer Communications · doi:10.1186/s40880-018-0331-y · Cited by 172
Qu, C., Wang, Y., Wang, P., Chen, K., Wang, M., Zeng, H., Lu, J., Song, Q., Diplas, B. H., Tan, D., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819799116 · Cited by 170
Self-citationTsilimigras, D. I., Bagante, F., Moris, D., Hyer, J. M., Sahara, K., Paredes, A. Z., Mehta, R., Ratti, F., Marques, H. P., Soubrane, O., et al. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08452-3 · Cited by 169
Hara, K., Takeda, A., Tsurugai, Y., Saigusa, Y., Sanuki, N., Eriguchi, T., Maeda, S., Tanaka, K., & Numata, K. (2019) · Hepatology · doi:10.1002/hep.30591 · Cited by 164
Sun, Y.-F., Guo, W., Xu, Y., Shi, Y.-H., Gong, Z.-J., Ji, Y., Du, M., Zhang, X., Hu, B., Huang, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1063 · Cited by 161
Self-citationSposito, C., Battiston, C., Facciorusso, A., Mazzola, M., Muscarà, C., Scotti, M., Romito, R., Mariani, L., & Mazzaferro, V (2016) · British Journal of Surgery · doi:10.1002/bjs.10137 · Cited by 160
Filgueira, N. A. (2019) · World Journal of Hepatology · doi:10.4254/wjh.v11.i3.261 · Cited by 152
Glantzounis, G. K., Tokidis, E., Basourakos, S. P., Ntzani, E., Lianos, G. D., & Pentheroudakis, G. E. (2016) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2016.05.026 · Cited by 141
EASL and AASLD recommendations for the diagnosis of HCC to the test of daily practice
Aubé, C., Oberti, F., Lonjon, J., Pageaux, G., Séror, O., Nkontchou, G., Rode, A., Radenne, S., Cassinotto, C., Vergniol, J., et al. (2017) · Liver International · doi:10.1111/liv.13429 · Cited by 134
Wang, Z., Peng, Y., Hu, J., Wang, X., Sun, H., Sun, J., Shi, Y., Xiao, Y., Ding, Z.-B., Yang, X., et al. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000002942 · Cited by 128
Self-citationHow Has Virtual Hepatectomy Changed the Practice of Liver Surgery?
Mise, Y., Hasegawa, K., Satou, S., Shindoh, J., Miki, K., Akamatsu, N., Arita, J., Kaneko, J., Sakamoto, Y., & Kokudo, N. (2017) · Annals of Surgery · doi:10.1097/sla.0000000000002213 · Cited by 122
Guo, W., Yang, X., Sun, Y., Shen, M., Ma, X., Wu, J., Zhang, C., Zhou, Y., Xu, Y., Hu, B., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0251 · Cited by 117
Self-citationWen, T., Chen, J., Facciorusso, A., Donadon, M., Han, H., Mao, Y., Dai, C., Cheng, S., Zhang, B., Peng, B., et al. (2018) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn.2018.08.01 · Cited by 116
Piscaglia, F., Wilson, S., Lyshchik, A. P., et al. (2017) · Ultraschall in der Medizin - European Journal of Ultrasound · doi:10.1055/s-0042-124661 · Cited by 106
Liu, X.-J., Jiang, H., Chen, J., Zhou, Y., Huang, Z., & Song, B. (2017) · Liver Transplantation · doi:10.1002/lt.24867 · Cited by 103
Tayob, N., Lok, A. S.-F., Do, K.-A., & Feng, Z. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.07.049 · Cited by 98
Cheung, T. T., Han, H., She, W. H., Chen, K.-H., Chow, P. K. H., Yoong, B. K., Lee, K., Kubo, S., Tang, C. N., & Wakabayashi, G. (2017) · Liver Cancer · doi:10.1159/000481834 · Cited by 91
Gardini, A. C., Tamburini, E., Iñarrairaegui, M., Frassineti, G. L., & Sangro, B. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s175715 · Cited by 85
Au, K. P., & Chok, K. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i45.5081 · Cited by 82
Li, C., Wang, M.-D., Lu, L., Wu, H., Yu, J.-J., Zhang, W., Pawlik, T. M., Zhang, Y., Zhou, Y.-H., Gu, W.-M., et al. (2019) · Hepatology International · doi:10.1007/s12072-019-09981-0 · Cited by 78
Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma
Yang, C., & Qin, S. (2018) · Cancer Medicine · doi:10.1002/cam4.1664 · Cited by 76
Pham, C. H., Fong, T., Zhang, J., & Liu, L. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy051 · Cited by 65
Identifying Clonal Origin of Multifocal Hepatocellular Carcinoma and Its Clinical Implications
Xie, D., Fan, H., Ren, Z., Fan, J., & Gao, Q. (2019) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000006 · Cited by 65
Self-citationLi, J., Wang, J., Lei, L., Yuan, G., & He, S. (2019) · European Radiology · doi:10.1007/s00330-019-06294-6 · Cited by 63
Hu, H., Han, H., Han, X. K., Wang, W. P., & Ding, H. (2017) · European Radiology · doi:10.1007/s00330-017-4900-2 · Cited by 37
A comparability study of immunohistochemical assays for PD-L1 expression in hepatocellular carcinoma
Shi, L., Zhang, S., Chen, J., Lu, S., Fan, X., TONG, J. H. M., Chow, C., Tin, E. K. Y., Chan, S. L., Chong, C. C. N., et al. (2019) · Modern Pathology · doi:10.1038/s41379-019-0307-8 · Cited by 24
Zhou, C., Peng, Y., Zhou, K., Zhang, L., Zhang, X., Yu, L., Hu, J., Chen, F., Qiu, S., Zhou, J., et al. (2019) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn.2018.11.19 · Cited by 22
Self-citation
Cited by
Li, Q.-J., He, M.-K., Chen, H.-W., Fang, W.-Q., Zhou, Y.-M., Xu, L., Wei, W., Zhang, Y.-J., Guo, Y., Guo, R.-P., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.00608 · Cited by 420
Du, Q., Yuan, J., & Ren, Z. (2024) · Liver Cancer · doi:10.1159/000534446 · Cited by 20
Self-citation
Metadata
- Authors
- Xie, D.-Y., Ren, Z.-G., Zhou, J., Fan, J., & Gao, Q.
- Venue
- Hepatobiliary Surgery and Nutrition
- Publisher
- AME Publishing Company
- Published
- 2020-08
- Volume
- 9
- Issue
- 4
- Pages
- 452-463
- ISSN
- 2304-3881 (ISSN-L)
- 2304-389X
- OpenAlex
- W3047155119
- Cited by
- 479
- References
- 86
- FWCI
- 38.89
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.